Skip to search formSkip to main contentSkip to account menu

Octreotide 1 MG/ML Injectable Solution

Known as: octreotide acetate 1000 ug in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [Octreotide Acetate], OCTREOTIDE ACETATE 1000 ug in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [Octreotide], OCTREOTIDE ACETATE 1000 ug in 1 mL SUBCUTANEOUS INJECTION, SOLUTION 
National Institutes of Health

Related topics

Related topics

22 relations
1 ML Octreotide 0.1 MG/ML InjectionAcetic AcidAcromegalyAdenoma

Broader (4)

AntidiarrhealsAntineoplastic AgentsOctreotideOctreotide Acetate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
[Safety and efficacy of transarterial embolization combined with octreotide LAR on reducing tumor burden for neuroendocrine tumor liver metastasis].
Objective: To evaluate the tumor burden reducing efficacy and safety of transcatheter arterial embolization (TAE) combined with… 
2017
2017
Diagnostic Computed Tomography Coregistration With In-111-DTPA-Octreotide Single Photon Emission Tomography/Low-Dose Computed Tomography
Objectives In-111-DTPA-octreotide (OctreoScan) is still pivotal for neuroendocrine tumor imaging, despite the introduction of Ga… 
2016
2016
Clinical Efficacy of PET/CT Using 68Ga-DOTATOC for Diagnostic Imaging
Positron emission tomography/computed tomography (PET/CT) using 68Ga-labelled DOTA0-Tyr3 octreotide (DOTATOC) is one of the… 
2016
2016
Role of 99mTc-HYNIC-Tyr3-octreotide scintigraphy in neuroendocrine tumors based on localization of the primary tumor.
BACKGROUND The aim of our work was to determine the accuracy of 99mTc-HYNIC Tyr3 octreotide scintigraphy (TcOS) in detecting… 
Highly Cited
2012
Highly Cited
2012
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor… 
Review
2010
Review
2010
The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy
111In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scintigraphy is currently the nuclear medicine imaging modality of… 
2005
2005
Evaluation of the therapeutic response to In-111-DTPA octreotide-based targeted therapy in liver metastatic neuroendocrine tumors according to CT/MRI/US findings.
Thirteen (13) patients with liver neuroendocrine carcinomas metastases, positive for somatostatin receptors, confirmed by… 
1999
1999
Untersuchungen zum Somatostatinrezeptor-Status bei nicht-medullären Schilddrüsenkarzinomen
Zusammenfassung Ziel: In aktuellen ln-vitro- und In-vivo-Untersuchungen wurde eine Somatostatinrezeptor-Expression bei einigen… 
Highly Cited
1999
Highly Cited
1999
High purity production and potential applications of copper-60 and copper-61.
Highly Cited
1998
Highly Cited
1998
Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats.
UNLABELLED The efficacy of 64Cu [T1/2 = 12.7 hr; beta+ (0.655 MeV; 19%); beta- (0.573 MeV; 40%)] as a radioisotope for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)